. "Appendix D: Forum Member and Staff Biographies." Managed Care Systems and Emerging Infections: Challenges and Opportunities for Strengthening Surveillance, Research, and Prevention, Workshop Summary. Washington, DC: The National Academies Press, 2000.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Managed Care Systems and Emerging Infections: Challenges and Opportunities for Strengthening Surveillance, Research, and Prevention, Workshop Summary
America (fellow), Pediatric Infectious Diseases Society, and American Academy of Pharmaceutical Physicians (Vice President, Membership Development Committee, and board member).
STEVEN J. BRICKNER, Ph.D., is Manager of Medicinal Chemistry at Pfizer Central Research, where he leads a team of medicinal chemists that is focused on the discovery and development of new antibacterial agents designed to meet the growing problems with resistance. He has more than 15 years of pharmaceutical industrial research experience, all directed at the discovery of novel antibiotics. Before joining Pfizer, he led a team that discovered and developed linezolid, the first oxazolidinone to undergo phase III clinical evaluation. Dr. Brickner is recognized as a world expert on this new class of antibacterial agents.
NANCY CARTER-FOSTER, M.S.T.M., is Director of the U.S. Department of State's Emerging Infectious Diseases Program and is responsible for heading the department's policy coordination on infectious diseases and human immunodeficiency virus-AIDS issues and integrating international health issues with economic and national security implications into U.S. foreign policy. She coordinates with the State Department's 250 embassies, missions, and agencies to address global infectious disease priorities and to effect a unified United States' government response. Ms. Carter-Foster has been a foreign affairs advisor to the then Majority Whip of the U.S. House of Representatives, Congressman William H. Gray, and was the U.S. chief negotiator on international population issues, and the roles and status of women and international health issues which lead to the United Nation's (UN) World Conference on Population and Development, the UN Conference on Environment and Development (UNCED), and a myriad of other bilateral and multilateral fora. She also has a background in environmental systems management, ocean affairs, law of the sea, and coastal zone development.
GAIL H. CASSELL, Ph.D., is Vice President, Infectious Diseases, Drug Discovery Research, and Clinical Investigation at Eli Lilly & Company. Previously, she was the Charles H. McCauley Professor and (since 1987) Chair, Department of Microbiology, University of Alabama Schools of Medicine and Dentistry at Birmingham, a department which ranked first in research funding from the National Institutes of Health since 1989 under her leadership. She is a member of the Director's Advisory Committee of the National Centers for Disease Control and Prevention, Dr, Cassell is past president of the American Society for Microbiology, a former member of the National Institutes of Health Director's Advisory Committee, and a former member of the Advisory Council of the National Institute of Allergy and Infectious Diseases. She also has served as an adviser on infectious diseases and indirect costs of research to the White House Office on Science and Technology and was previously chair of the Board of Scientific Councilors of the Center for Infectious Diseases Centers for the National Centers for Disease Control and Prevention. Dr. Cassell served 8 years on the Bacte